Background {#Sec1}
==========

Globally, the number of people with diabetes has increased at an alarming level, and diabetes is placing a heavy economic burden on families and healthcare systems. The number of people with diabetes was estimated at more than 371 million in 2012, and is expected to be 551.9 million in 2030 \[[@CR1]\]. China has become the country with the largest number of people with diabetes in the world. The most recent study estimated that the prevalence of diabetes among a representative sample of Chinese adults was 11.6% and the prevalence of pre-diabetes was 50.1%, which corresponded to 113.9 million and 493.4 million people, respectively, in 2010 \[[@CR2]\]. The Chinese Diabetes Society of the Chinese Medical Association and International Diabetes Federation estimated that 13% of total medical expenditures in China were directly caused by diabetes in 2010 \[[@CR3]\].

Diabetes is a debilitating disease characterized by deficiencies in insulin secretion, insulin action, or both, leading to chronic hyperglycaemia \[[@CR4]\]. Insulin treatment is the inevitable choice for people with type 2 diabetes (T2DM) as diabetes progresses. It is typically used after glycaemic control fails or is not maintained with lifestyle changes and combinations of oral anti-diabetic medications \[[@CR5]\]. Insulin treatment can improve glycaemic control, prevent the development of long-term complications of diabetes \[[@CR6]\], and influence patients' quality of life \[[@CR7]\].

There are a few studies concerning the impacts of insulin use on patients' health-related quality of life (HRQoL), with the impacts recorded ranging from positive \[[@CR8]-[@CR10]\] to negative \[[@CR11]-[@CR13]\]. There are no studies regarding whether insulin therapy improves or decreases patients' quality of life in a Chinese setting. The purpose of this study was to assess how HRQoL changed, and the predictors of such changes, after starting with, or switching to, biphasic insulin aspart 30 (BIAsp 30, 30% soluble insulin aspart, 70% protamine-crystallized insulin aspart) over a 24-week period among people with T2DM in China using Chinese subgroup data from the A~1~chieve®, study \[[@CR14]\].

Methods {#Sec2}
=======

Study design {#Sec3}
------------

A~1~chieve® was a 24-week, international, prospective, multicentre, non-interventional, observational study of people with T2DM in non-Western countries who had begun using basal insulin detemir, bolus insulin aspart and premixed insulin BIAsp 30, alone or in combination \[[@CR14]\]. It was the largest observational study ever conducted in insulin therapy and was carried out in 28 countries across four continents (Asia, Africa, South America and Europe). Individuals with type 2 diabetes with no prior history of using the study insulins previously, and who had been started on one of the insulins in the 4 weeks prior to the study start are eligible for this study. People with hypersensitivity to the study insulins or excipients, and women who were pregnant, breast feeding, or who intended to become pregnant within 6 months of the study are excluded. The therapies were prescribed by the physicians in the course of normal clinical practice and treatment demand rather than randomly assigned by the researchers. The study was conducted in accordance with the Declaration of Helsinki. The ethics committee approval was obtained for each country, and all participants gave written, informed consent prior to their inclusion in the study. In China, central ethics committee approval was performed in China-Japan Friendship Hospital. The coordinating sites accept the central ethics committee approval or further conduct the ethics committee approval by ethics committee of their own hospitals (Additional file [1](#MOESM1){ref-type="media"}).

The Chinese cohort that either started (6,612) or were switched (1,966) to BIAsp 30 in the A~1~chieve® study consisted of 8,578 people with T2DM from 130 urban hospitals in China. They were recruited between January 2009 and June 2010, and had an average observation period of six months. Approval from ethics committees were obtained at all the study sites.

Clinical endpoints {#Sec4}
------------------

Clinical endpoints including safety and effectiveness outcomes were evaluated. Safety assessment included the incidence of serious adverse drug reactions (SADRs), including major hypoglycaemic events, the change in number of hypoglycaemic, the change in number of nocturnal hypoglycaemic event, and the number of adverse drug reactions (ADRs) from baseline to final visit. Effectiveness assessments included change in Haemoglobin A1c (HbA1c), fasting plasma glucose (FPG), postprandial plasma glucose (PPG), body weight between baseline and interim and final visits, and change in systolic blood pressure (SBP) and lipid profile at the final visit.

HRQoL measurement {#Sec5}
-----------------

The HRQoL was measured by the Chinese version of EQ-5D questionnaire at baseline and after 24 weeks of therapy. The EQ-5D consists of a descriptive system of five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each of the five dimensions can take one of three responses recording different level of severity: no problems, some or moderate problems and extreme problems. These responses could be converted into a single utility value using the EQ-5D preference weights elicited from general population samples. The EQ-5D also includes a visual analogue scale (VAS) recording the respondents' direct valuation of their current HRQoL state on a graduated (0 − 100) scale with higher scores for higher HRQoL \[[@CR15]\]. The Chinese version of the EQ-5D was obtained from the EuroQol Group \[[@CR16]\]. Its validity and reliability have been assessed in mainland China \[[@CR17]-[@CR19]\] and it has been used for studies of different populations in mainland China \[[@CR20]-[@CR22]\].

Statistical analyses {#Sec6}
--------------------

Descriptive analysis and multivariable regression were performed using SAS (Version 9.1.3, SAS Institute Inc., NC 27513-2414, USA). The change from baseline to 24 weeks in clinical endpoints, HRQoL with the EQ-5D VAS, and health utility value as continuous variables, were analysed with the Wilcoxon signed-rank test. The UK preference weights were used for calculation of EQ-5D utility value because Chinese preference weights were still to be established.

The change in the percentage of people reporting no problem in EQ-5D descriptive dimensions was analysed with a chi-square test. For descriptive analysis, the total cohort was divided into subgroups of insulin-naïve people (those not taking insulin therapy at baseline) and previously insulin-experienced people (current insulin users). Linear OLS regression was further employed to explore predictors of the changes in EQ-5D score. Independent variables included patients' demographics (age and sex), health conditions (macro-complications, micro-complications, duration of diabetes, body mass index (BMI), HbA~1c~, SBP, total cholesterol, high-density lipoprotein (HDL) and low-density lipoprotein (LDL)), and other related indicators (previous insulin experience, total hypoglycaemia and major hypoglycaemia) at baseline.

Results {#Sec7}
=======

Demographics and characteristics of respondents {#Sec8}
-----------------------------------------------

Among the 8,578 people with T2DM, 1,966 (22.9%) were in the insulin-experienced group and 6,612 (77.1%) in the insulin-naïve group. The average age was 54.9 (±14.4) years, and BMI was 24.7 (±3.3) kg/m^2^ for the total cohort. The average duration of diabetes was 6.0 (±6.0) years, with 9.3 (±6.8) for the insulin-experienced group and 5.0 (±5.4) for the insulin-naïve group (Table [1](#Tab1){ref-type="table"}).Table 1**Characteristics of A** ~**1**~ **chieve** **®** **study respondents in insulin-naïve and insulin-experienced groups, and in the total cohortInsulin experienced N = 1966Insulin naïve N = 6612Total cohort N = 8578**GenderMale, %1104 (56.2)3786 (57.3)4890 (57.0)AgeYears, mean (sd)56.7 (15.2)54.3 (14.2)54.9 (14.4)WeightKg, mean (sd)68.2 (11.2)68.1 (11.6)68.1 (11.5)BMIKg/m^2^, mean (sd)24.8 (3.3)24.6 (3.3)24.7 (3.3)Duration of diabetesYears, mean (sd)9.3 (6.8)5.0 (5.4)6.0 (6.0)

Clinical endpoints {#Sec9}
------------------

Blood glucose control measures improved markedly in both insulin-naïve and prior insulin users after 24 weeks of therapy with BIAsp 30. HbA~1c~ decreased from 9.5% to 7.0% for the total cohort, with a decrease from 9.1% to 7.0% for prior insulin users and a decrease from 9.6% to 7.0% for the insulin-naïve group. From a similar baseline measure, body weight of the two groups increased slightly by 0.3 kg during the therapy. No major hypoglycaemia was observed during the study, and reported hypoglycaemia rates (including overall, nocturnal and minor hypoglycaemia) decreased in the total cohort and in both subgroups. All of these results indicated BIAsp 30 could improve blood glucose control without increasing the risk of hypoglycaemia (Table [2](#Tab2){ref-type="table"}). Indicators including FPG, PPG, SBP, LDL and HDL changed favourably, and no SADR was reported during the study period \[[@CR23]\].Table 2**HbA** ~**1c**~ **, body weight and hypoglycaemia in insulin-naïve and insulin-experienced patients, and in the total cohortInsulin-experienced, N = 1,966Insulin-naïve, N = 6,612Total cohort, N = 8,578**HbA~1c~ (%)N105633864442Baseline9.1 (2.3)9.6 (2.2)9.5 (2.3)Week 247.0 (1.1)7.0 (1.0)7.0 (1.0)Change-2.0 (2.2)-2.7 (2.2)-2.5 (2.2)P value\<0.001\<0.001\<0.001Body weight (kg)N145946006059Baseline68.7 (11.2)68.5 (11.3)68.5 (11.3)Week 2469.2 (10.9)68.8 (10.8)68.9 (10.8)Change0.5 (3.0)0.3 (3.1)0.3 (3.1)P value\<0.001\<0.001\<0.001Overall hypoglycaemia (events/patient year)N196666128578Baseline6.121.22.32Week 242.141.371.54Nocturnal hypoglycaemia (events/patient year)N196666128578Baseline1.650.260.58Week 240.420.240.28Major hypoglycaemia (events/patient year)N196666128578Baseline0.370.090.15Week 240.000.000.00Minor hypoglycaemia (events/patient year)N196666128578Baseline5.751.102.17Week 242.141.371.54Data are mean (sd), n or incidence.

Quality of life {#Sec10}
---------------

### Quality of life in the total cohort {#Sec11}

As measured by VAS from the EQ-5D (on a scale of 0--100), reported QoL of the total cohort increased by 6.2 from 75.8 at baseline to 82.0 at 24 weeks (p \< 0.001). The health utility value (on a scale of 0--1) increased by 0.018 from 0.875 at baseline to 0.893 at 24 weeks (p \< 0.001).

The increased percentages of people reporting no problem on the descriptive EQ-5D dimensions indicated that there were improvements of HRQoL after BIAsp 30 treatment. The percentages of patients reporting no problems in three of the five dimensions of EQ-5D---mobility, pain/discomfort and anxiety/depression---increased significantly from 88.4% to 91.4% (p \< 0.0001), 77.3% to 82.8% (p \< 0.0001) and 74.2% to 77.1% (p = 0.002) after 24 weeks, respectively. There was no statistical significance found in the percentage of patients who reported no problems in self-care or who reported no problems in usual activities (Table [3](#Tab3){ref-type="table"}).Table 3**Quality of life in insulin-naïve and insulin-experienced patients, and in the total cohortInsulin-experienced, N = 1,966Insulin-naïve, N = 6,612Total cohort, N = 8,578**EQ-5D VAS (Scale 0-100)N139047136103Baseline75.3 (14.1)75.9 (13.4)75.8 (13.6)Week 2482.0 (11.3)82.0 (10.3)82.0 (10.6)Change6.7 (15.8)6.1 (14.4)6.2 (14.7)P value\<0.001\<0.001\<0.001QoL UK (Scale 0-1)N140648146220Baseline0.851 (0.190)0.882 (0.176)0.875 (0.179)Week 240.886 (0.170)0.896 (0.157)0.893 (0.160)Change0.035 (0.228)0.014 (0.218)0.018 (0.221)P value\<0.001\<0.001\<0.001Mobility dimensionN141648436259No problems with walking (%)Baseline1197 (84.5)4333 (89.5)5530 (88.4)Week 241289 (91.0)4433 (91.5)5722 (91.4)P value\<0.00010.0005\<0.0001Self-care dimensionN141548456260No problems with self-care (%)Baseline1301 (91.9)4475 (92.4)5776 (92.3)Week 241280 (90.5)4483 (92.5)5763 (92.1)P value0.16350.75840.6655Usual activities dimensionN141548416256No problems with performing usual activities (%)Baseline1222 (86.4)4316 (89.2)5538 (88.5)Week 241236 (87.3)4272 (88.2)5508 (88.0)P value0.43610.15780.4043Pain/discomfort dimensionN141148326243No pain or discomfort (%)Baseline1007 (71.4)3820 (79.1)4827 (77.3)Week 241138 (80.7)4031 (83.4)5169 (82.8)P value\<0.0001\<0.0001\<0.0001Anxiety/depression dimensionN141348376250Not anxious or depressed (%)Baseline1014 (71.8)3624 (74.9)4638 (74.2)Week 241067 (75.5)3749 (77.5)4816 (77.1)P value0.02360.00280.0002Data are mean (sd), n or percentage.

### Quality of life for prior insulin-experienced and insulin-naïve subgroups {#Sec12}

Quality of life improved in both insulin-experienced and insulin-naïve patients. Baseline EQ-5D VAS scores were similar for both prior insulin-experienced and insulin-naïve subgroups (75.3, 75.9). There was a significant increase in both subgroups after 24 weeks (+15.8, +14.4, p \< 0.001). The baseline health utility value of the insulin-experienced group (0.851) was lower than that of the insulin-naïve group (0.882). After 24 weeks, the health utility value of the insulin-experienced and insulin-naïve groups increased by 0.035 (p \< 0.001) and 0.014 (p \< 0.001) resulting in a similar health utility value between the two groups.

The percentages of patients reporting no problems in dimensions of mobility, pain/discomfort and anxiety/depression increased significantly from 84.5% to 91.0% (p \< 0.0001), 71.4% to 80.7%(p \< 0.0001) and 71.8% to 75.5% (0.0236), respectively, for the prior insulin-experienced group, and from 89.5% to 91.5% (p = 0.0005), 79.1% to 83.4%(p \< 0.0001) and 74.9% to 77.5% (p = 0.0028), respectively, for the insulin-naïve group. Decrease in percentages of patients reporting no problems were seen in the self-care dimension for the prior insulin-experienced group (from 91.9% to 90.5%) and in the usual activities dimension (from 89.2% to 88.2%) for the prior insulin-naïve group, but neither change was statistically significant. There were similar percentages of patients reporting no problems across all other dimensions between the two groups (Table [3](#Tab3){ref-type="table"}).

### Linear OLS regression for the change in EQ-5D score {#Sec13}

Patients with higher HbA~1c~ levels at baseline, having major hypoglycaemia or micro-complications exhibited significantly larger changes in EQ-5D scores than those with lower baseline HbA~1c~ levels, without major hypoglycaemia or micro-complications after controlling for demographics and other baseline characteristics. HDL and LDL at baseline were negatively associated with change in EQ-5D scores. Other variables such as age, sex, duration of diabetes, and patients' prior insulin experience were not significantly associated with change in HRQoL (Table [4](#Tab4){ref-type="table"}).Table 4**Multivariate linear regression for change in EQ-5D VAS scoreVariablesCoefficientP-value**Intercept5.43770.1041Macro-complications (yes = 1, no = 0)-0.60640.3188Micro-complications (yes = 1, no = 0)1.42260.0067Duration of diabetes0.029930.5239Age0.024030.2699Male-0.8390.0944BMI at baseline-0.14540.0554Pre_study treatment (Insulin naïve = 1, insulin users = 0)-0.54740.3547HbA~1c~ at baseline0.34590.0013SBP at baseline0.02080.1661Total cholesterol at baseline0.45280.0817HDL at baseline-2.3537\<.001LDL at baseline-0.75430.0138Total hypoglycaemia at baseline (yes = 1, no = 0)0.014570.9628Major hypoglycaemia at baseline (yes = 1, no = 0)6.957\<.001

Discussion {#Sec14}
==========

This was the first study examining the impact of BIAsp 30 on HRQoL of people with T2DM in China. The result showed that people with T2DM starting with, or switching to, BIAsp 30 experienced significantly increased HRQoL over 24 weeks. The findings of this study were consistent with previous studies \[[@CR24],[@CR25]\] in other countries based on A~1~chieve® that evaluated how patients' HRQoL changed after BIAsp 30 treatment.

The efficacy and safety of BIAsp 30 compared with other insulins were shown in randomized controlled trials \[[@CR26]-[@CR30]\], and the effectiveness of BIAsp 30 in near-routine clinical practice was demonstrated by observational studies \[[@CR31],[@CR32]\]. This study extended the results from clinical outcomes of BIAsp 30 and added additional evidence for decision making by assessment of humanistic outcomes. HRQoL was considered as a multidimensional concept reflecting patients' subjective perceptions of their physical, mental and social functioning \[[@CR33]\]. Measuring HRQoL provided a way to know patients' subjective perceptions of clinical practice, and allowed a comprehensive evaluation of the health intervention. There was evidence that proper assessment of HRQoL during healthcare management can result in improvements to the patients' health \[[@CR34]\].

BIAsp30 treatment could be the most likely factor for improvements in HRQoL in this study. After treatment of BIAsp30, the patients' glycaemic control improved and rates of hypoglycaemic events decreased, and it is recognized both of these could lead to improvement in HRQoL \[[@CR35],[@CR36]\]. However, since the A~1~chieve® was non-randomised and lacked a standardised treatment protocol, it should be noted that factors other than BIAsp 30 therapy itself could contribute to the improvements as well. The circumstances in which BIAsp 30 was started were unknown, and patients' self-management activities might be enhanced. Concomitant medication and dietary intake were not controlled either \[[@CR14]\].

In addition to the impact of BIAsp 30 therapy on HRQoL, this paper also examined predictors for such impacts. The results of multivariable linear regression showed patients with a higher HbA~1c~ level, major hypoglycaemia or micro-complications at baseline experienced a larger amount of change in their EQ-5D scores. This finding indicates that patients with worse health conditions at baseline were more likely to experience larger improvements of HRQoL than those with better health conditions.

There were several limitations in this study. First, because evaluation of HRQoL was based on the observational A~1~chieve® study, which was non-randomised and lacked a standardised treatment protocol, confounding factors such as improvement of life style might affect patients' HRQol. Second, the UK preference weights used for utility calculations of EQ-5D in this study might differ from those of comparable Chinese weights and result in an inaccurate evaluation of change in HRQoL in Chinese people with T2DM. Moreover, although EQ-5D has been widely used in treatment evaluation for diabetes, disease-specific questionnaires are often regarded as more sensitive than generic measures such as EQ-5D for capturing the impact of treatment \[[@CR6]\]. All of these issues leave room for future research.

Conclusion {#Sec15}
==========

This study suggested that BIAsp 30 treatment was associated with improved glycaemic control and HRQoL in people with T2DM in China. Patients with worse health conditions were more likely to experience larger improvements of HRQoL than those with better health conditions.

Additional file {#Sec16}
===============

Additional file 1:**130 hospitals and EC information for A** ~**1**~ **chieve study in China.**
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